[Skip to Navigation]
July 30, 2020

A Case of Extracellular Signal-Regulated Kinase Inhibitor–Associated Retinopathy

Author Affiliations
  • 1Retina Service, Storm Eye Institute, Medical University of South Carolina, Charleston
JAMA Ophthalmol. 2020;138(9):1002-1004. doi:10.1001/jamaophthalmol.2020.2716

Mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor–associated retinopathy (MEKAR) is typically associated with isolated, self-limited serous retinal detachment.1,2 Here, we report what is, to our knowledge, the first case of extracellular signal-regulated kinase (ERK) inhibitor–associated retinopathy (ERKAR), following treatment with a first-in-class ERK1/ERK2 inhibitor BVD523 (ulixertinib).

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words